Ubiquitin-dependent mechanisms have been implicated in the regulation of most if not all hallmarks of GBM, in particular the signal transduction pathways that confer cancer cells properties but also stemness and heterogeneity which have so far hindered the use of potential treatments through mediating drug resistance. Here, UBA52 is linked to cancer.